IDEAYA Biosciences said on Monday that its drug for a type of eye cancer met the main goal of a mid-to-late-stage trial after showing improved patient survival without disease progression, sending its shares up 39.2% in premarket trading.
Read More – GSK sees blockbuster potential in its targeted cancer therapy following promising early-stage data
The drug, darovasertib, when used in combination with Pfizer’s Xalkori, improved median survival to 6.9 months compared with 3.1 months for other therapies selected by the trial investigators.
Five complete responses were observed in the darovasertib combination group, meaning all detectable signs of cancer disappeared.
